Trial Profile
Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Adalimumab; Etanercept
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 24 Nov 2008 Status changed from not yet recruiting to withdrawn prior to recruitment, reported by ClinicalTrials.gov.
- 19 Aug 2008 New trial record.